| Response 6 months | Baseline | 6 months | Response 12 months | Baseline | 12 months |
---|---|---|---|---|---|---|
Anti-MCV, U/mL | Responders (n = 11) | 654 (89–2,918) | 535 (56–3,000) | Responders (n = 15) | 293 (61–2,918) | 117a (48–3,582) |
 | Nonresponders (n = 12) | 307 (60–1,145) | 227 (40–1,234) | Nonresponders (n = 8) | 363 (60–1,145) | 227 (47–1,500) |
Anti-CCP, U/mL | Responders (n = 11) | 1,402 (83–11,360) | 1,300 (54–11,370) | Responders (n = 15) | 1,246 (83–11,360) | 837b (48–12,640) |
 | Nonresponders (n = 12) | 962 (130–4,232) | 1,134 (74–2,392) | Nonresponders (n = 8) | 1,169 (275–4,232) | 1,331 (126–4,313) |
IgM-RF, IU/mL | Responders (n = 11) | 91.5 (10–424) | 58 (10–216) | Responders (n = 15) | 74.5 (9–781) | 49.5c (10–214) |
 | Nonresponders (n = 12) | 205 (9–949) | 133c (10–367) | Nonresponders (n = 8) | 283 (14–949) | 152c (35–463) |